A H₃ antagonist for treating allergic rhinitis: a development candidate?

Abstract

The application claims a single 1,4-disubstituted piperazine derivative, a H₃ antagonist, and its use for the treatment of inflammatory diseases, especially allergic rhinitis. Compositions of the agent alone or in combination with a H₁ antagonist are claimed. The antagonist is indicated to have low CNS penetration.

Keywords::

• allergic rhinitis
• GW-784568X
• H₃ antagonist
• histamine

Patent Details

• Title l-{4-[(l-Cyclobutyl-4-piperidinyl)oxy]- phenyl]-4-{[4-(methylsulfonyl)phenyl]carbonyl piperazin as histamin H₃ antagonist.

• Assignee Glaxo Group Ltd.

• Inventors Hancock AP, Hodgson ST, Vinader BM, Washington ML.

• Priority date 24/02/05.

• Filing date 22/02/06.

• Publication date 31/08/06.

• Publication no. WO2006090142.